MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MAIA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of MAIA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MAIA's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to MAIA
Recent picks made for MAIA stock on CNBC
ETFs with the largest estimated holdings in MAIA
Flights by private jets registered to MAIA